

Transdermal Granisetron in the Treatment of Hyperemesis Gravidarum

Ms Rebecca Butler-Mader¹, Miss Isabelle Fassbind¹, Dr Ann-Maree Craven²

¹Royal Brisbane and Women's Hospital Pharmacy Department, ²Royal Brisbane and Women's Hospital Obstetric Medicine

Background

Nausea and vomiting is common in early pregnancy.¹ Hyperemesis Gravidarum (HG) is a severe form of nausea and vomiting characterised by hypovolaemia and weight loss.^{1,2} HG occurs less frequently, affecting around 0.3-1% of pregnancies.² It is the most common cause of hospitalisation in early pregnancy.²

Maternal complications include malnutrition and multiple vitamin deficiencies.² Oesophageal trauma may result from prolonged vomiting.² Although a casual relationship is uncertain, HG is associated with psychological morbidity, including social dysfunction, anxiety, insomnia, and depression.² The physical and psychological burden of HG has also been associated with elective termination of pregnancy.² Foetal complications include preterm birth, low birthweight and small-for-gestational age.²

Treatment of HG involves multiple pharmaceutical agents, including antiemetics and other medications, contributing to significant tablet and financial burden (see figure 1). Ondansetron is used where first-line antiemetics have failed, and preferably after the first trimester of pregnancy, due to mixed safety data.³ A large retrospective study found no increased risk of major birth defect, stillbirth, preterm labour or small-for-gestational age. Other studies have found a possible association with cardiovascular defects and cleft palate with first trimester exposure.³

Objectives

This report aims to share our experience of using oral and transdermal granisetron to improve HG, thereby contributing to current limited evidence.

Literature Review

Granisetron is a selective 5-hydroxytryptamine (5-HT₃) receptor antagonist indicated for chemotherapy-induced or post-operative nausea and vomiting.⁴ Currently there is limited safety and efficacy data for granisetron use in pregnancy and it is categorised B1 per the Therapeutic Goods Administration (TGA).⁴ Studies by Aleyasin of 32 women, and Caritis of 16 women, concluded that oral and transdermal granisetron decreased nausea and vomiting in pregnancy.^{5,6} A further study by Shapira of 80 women found no association with adverse neonatal outcomes.⁷

Clinical Features

A 28-year-old primip, with unremarkable previous medical history, presented to the Obstetric Medicine Outpatient Clinic at the Royal Brisbane and Women's Hospital at 24 weeks gestation for HG management on the background of multiple hospital admissions. Her symptoms included unrelenting nausea with associated vomiting. This occurred throughout the day, and of particular concern, for 2 hours each morning. Interestingly, her symptoms were unrelieved by oral ondansetron and prochlorperazine. The patient experienced reduced oral intake, weight loss, inability to work and reduced quality of life.



Figure 1: visual representation of our patient's medications required or related to the management of HG


Drug	Ondansetron	Granisetron
Form	Oral	Oral / Transdermal
Half life	3-6.2 hours	9 hours / 3-14 hours
Peak	1.6-2.2 hours	1.9 hours / 48 hours
Duration of action	8 hours	24 hours / 24-168 hours

Table 1: pharmacokinetic profile of ondansetron and granisetron^{8,9}

References

1. Uptodate. Treatment and outcome of nausea and vomiting of pregnancy. Uptodate; 2019. Available from <https://www.uptodate.com/contents/treatment-and-outcome-of-nausea-and-vomiting-of-pregnancy?search=hyperemesis%20hypovolaemia%20and%20weight%20loss.&source=search_result&selectedTitle=1-150&usage_type=default&display_rank=1> 2. Boelig RC, Barton SJ, Saccone G, Kelly AJ, Edwards SJ, Berghella V. Interventions for treating hyperemesis gravidarum. Cochrane Database of Systematic Reviews 2016, Issue 5 3. Royal College of Obstetricians & Gynaecologists green-top guideline. The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum. Royal College of Obstetricians & Gynaecologists; June 2016. Available from <https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg69-hyperemesis.pdf> 4. Granisetron-AFT (Granisetron) Australian approved product information. AFT Pharmaceuticals. Approved 2013 5. Caritis S, Zhao Y, Chen H-J, et al. Pharmacodynamics of transdermal Granisetron in women with nausea and vomiting of pregnancy. Am J of Obstet Gynaecol 2016;215:93.e1-4 6. Aleyasin A, Safarieh E, Turkamandi H, et al. Comparison of Efficacy of Granisetron and Promethazine in Control of Hyperemesis Gravidarum. J Obstet Gynaecol India. 2016;66(6):409-414. doi:10.1007/s13224-015-0709-6 7. Shapira M, Ayrahani I, Mazaki-Tovi S, Barzilay E. Safety of in utero exposure to Granisetron in first and second trimester. Am J Obstet Gynecol 2018; S100 8. Micromedex Solutions. Ondansetron. Greenwood Village (CO): Truven Health Analytics; 2019. Available from <http://www.micromedexsolutions.com> 9. Micromedex Solutions. Granisetron. Greenwood Village (CO): Truven Health Analytics; 2019. Available from <http://www.micromedexsolutions.com> 9. Sancuso (Transdermal Granisetron) summary of product characteristics. Germany: Pharbit/Waltrap GmbH. Approved 20 April 2012, renewal 9 January 2017 10. Sancuso (Granisetron Transdermal System) product information. United States. Approved September 2019

Patient Progress and Outcomes



Pharmacist Interventions

- Advice on switch from oral to transdermal forms, including timing of last oral dose.
- Assessment, literature review and advice around patch adhesion and application
- Recommendation to increase frequency of patch application, taking into consideration pharmacokinetics and peak plasma concentration (see figure 2).
- Educating the patient on medications including potential adverse effects and safety in pregnancy.
- Sourcing stock, given special access scheme requirements of transdermal product.

Mean Plasma Concentration of Granisetron (mean ± SD)




Figure 2: Mean plasma concentration curve of transdermal granisetron¹⁰

Conclusion

Granisetron, particularly in transdermal form, drastically improved symptoms of HG, evident by a reduction of nausea, cessation of vomiting, improved oral intake and weight gain. Granisetron use also led to a reduction in hospital admissions and associated healthcare costs. Granisetron in the future, may form part of the standard therapy for HG although this requires further research. This case highlights that alternative routes may be necessary in the treatment of HG. In our patient a successful vaginal delivery of a healthy baby girl weighing 2498g at 36 weeks and 5 days was achieved.

